AUG 20, 2026 · PHASE 2 TRIAL
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
ClinicalTrials.gov
Phase 2 interventional trial with planned enrollment of 333 participants comparing PF-07220060 plus fulvestrant to physician's choice in HR+/HER2− advanced breast cancer; registry record reports no results yet.
Reported
Planned enrollment333
PhasePhase 2
Primary outcome measureProgression-Free Survival (PFS) progression…